These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

281 related articles for article (PubMed ID: 26348634)

  • 1. Frequent TERT Promoter Mutations in Ocular Surface Squamous Neoplasia.
    Scholz SL; Thomasen H; Reis H; Möller I; Darawsha R; Müller B; Dekowski D; Sucker A; Schilling B; Schadendorf D; Steuhl KP; Paschen A; Westekemper H; Meller D; Griewank KG
    Invest Ophthalmol Vis Sci; 2015 Sep; 56(10):5854-61. PubMed ID: 26348634
    [TBL] [Abstract][Full Text] [Related]  

  • 2. TERT promoter mutations in periocular carcinomas: implications of ultraviolet light in pathogenesis.
    Lin SY; Liao SL; Hong JB; Chu CY; Sheen YS; Jhuang JY; Tsai JH; Liau JY
    Br J Ophthalmol; 2016 Feb; 100(2):274-7. PubMed ID: 26472403
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunohistochemical and mutational status of telomerase reverse transcriptase in conjunctival squamous cell carcinoma.
    Jayaraj P; Sen S; Saxena K; Gupta J; Vats P; Kashyap S; Chauhan S; Pushker N
    Indian J Ophthalmol; 2022 Mar; 70(3):971-975. PubMed ID: 35225554
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Telomerase promoter mutations in human immunodeficiency virus-related conjunctiva neoplasia.
    Starita N; Buonaguro L; Buonaguro FM; Tornesello ML
    J Transl Med; 2018 Mar; 16(1):77. PubMed ID: 29562930
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prevalence and implications of TERT promoter mutation in uveal and conjunctival melanoma and in benign and premalignant conjunctival melanocytic lesions.
    Koopmans AE; Ober K; Dubbink HJ; Paridaens D; Naus NC; Belunek S; Krist B; Post E; Zwarthoff EC; de Klein A; Verdijk RM;
    Invest Ophthalmol Vis Sci; 2014 Aug; 55(9):6024-30. PubMed ID: 25159205
    [TBL] [Abstract][Full Text] [Related]  

  • 6. TERT promoter hot spot mutations are frequent in Indian cervical and oral squamous cell carcinomas.
    Vinothkumar V; Arunkumar G; Revathidevi S; Arun K; Manikandan M; Rao AK; Rajkumar KS; Ajay C; Rajaraman R; Ramani R; Murugan AK; Munirajan AK
    Tumour Biol; 2016 Jun; 37(6):7907-13. PubMed ID: 26700669
    [TBL] [Abstract][Full Text] [Related]  

  • 7. TERT promoter mutations in penile squamous cell carcinoma: high frequency in non-HPV-related type and association with favorable clinicopathologic features.
    Kim SK; Kim JH; Han JH; Cho NH; Kim SJ; Kim SI; Choo SH; Kim JS; Park B; Kwon JE
    J Cancer Res Clin Oncol; 2021 Apr; 147(4):1125-1135. PubMed ID: 33635430
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Telomerase reverse transcriptase (TERT) promoter mutations are rare in urachal cancer.
    Thiem S; Herold T; Krafft U; Bremmer F; Tolkach Y; Szász AM; Kriegsmann J; Gaisa NT; Niedworok C; Szarvas T; Reis H
    Pathol Int; 2017 Dec; 67(12):597-601. PubMed ID: 29047227
    [TBL] [Abstract][Full Text] [Related]  

  • 9. TERT promoter mutations are frequent in cutaneous basal cell carcinoma and squamous cell carcinoma.
    Griewank KG; Murali R; Schilling B; Schimming T; Möller I; Moll I; Schwamborn M; Sucker A; Zimmer L; Schadendorf D; Hillen U
    PLoS One; 2013; 8(11):e80354. PubMed ID: 24260374
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prevalence of promoter mutations in the TERT gene in oral cavity squamous cell carcinoma.
    Chang KP; Wang CI; Pickering CR; Huang Y; Tsai CN; Tsang NM; Kao HK; Cheng MH; Myers JN
    Head Neck; 2017 Jun; 39(6):1131-1137. PubMed ID: 28230921
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Distinct profiles of TERT promoter mutations and telomerase expression in head and neck cancer and cervical carcinoma.
    Annunziata C; Pezzuto F; Greggi S; Ionna F; Losito S; Botti G; Buonaguro L; Buonaguro FM; Tornesello ML
    Int J Cancer; 2018 Sep; 143(5):1153-1161. PubMed ID: 29603728
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Heterogeneity of TERT promoter mutations status in squamous cell carcinomas of different anatomical sites.
    Cheng KA; Kurtis B; Babayeva S; Zhuge J; Tantchou I; Cai D; Lafaro RJ; Fallon JT; Zhong M
    Ann Diagn Pathol; 2015 Jun; 19(3):146-8. PubMed ID: 25862495
    [TBL] [Abstract][Full Text] [Related]  

  • 13. TERT promoter hotspot mutations and their relationship with TERT levels and telomere erosion in patients with head and neck squamous cell carcinoma.
    Boscolo-Rizzo P; Giunco S; Rampazzo E; Brutti M; Spinato G; Menegaldo A; Stellin M; Mantovani M; Bandolin L; Rossi M; Del Mistro A; Tirelli G; Dei Tos AP; Guerriero A; Niero M; Da Mosto MC; Polesel J; De Rossi A
    J Cancer Res Clin Oncol; 2020 Feb; 146(2):381-389. PubMed ID: 31960186
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Telomerase reverse transcriptase promoter mutations in tumors originating from the adrenal gland and extra-adrenal paraganglia.
    Papathomas TG; Oudijk L; Zwarthoff EC; Post E; Duijkers FA; van Noesel MM; Hofland LJ; Pollard PJ; Maher ER; Restuccia DF; Feelders RA; Franssen GJ; Timmers HJ; Sleijfer S; de Herder WW; de Krijger RR; Dinjens WN; Korpershoek E
    Endocr Relat Cancer; 2014 Aug; 21(4):653-61. PubMed ID: 24951106
    [TBL] [Abstract][Full Text] [Related]  

  • 15. TERT promoter mutation is uncommon in acral lentiginous melanoma.
    Liau JY; Tsai JH; Jeng YM; Chu CY; Kuo KT; Liang CW
    J Cutan Pathol; 2014 Jun; 41(6):504-8. PubMed ID: 24588324
    [TBL] [Abstract][Full Text] [Related]  

  • 16. TERT promoter mutation as an early genetic event activating telomerase in follicular thyroid adenoma (FTA) and atypical FTA.
    Wang N; Liu T; Sofiadis A; Juhlin CC; Zedenius J; Höög A; Larsson C; Xu D
    Cancer; 2014 Oct; 120(19):2965-79. PubMed ID: 24898513
    [TBL] [Abstract][Full Text] [Related]  

  • 17. TERT promoter mutations in ocular melanoma distinguish between conjunctival and uveal tumours.
    Griewank KG; Murali R; Schilling B; Scholz S; Sucker A; Song M; Süsskind D; Grabellus F; Zimmer L; Hillen U; Steuhl KP; Schadendorf D; Westekemper H; Zeschnigk M
    Br J Cancer; 2013 Jul; 109(2):497-501. PubMed ID: 23799844
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Telomerase reverse transcriptase promoter mutations in bladder cancer: high frequency across stages, detection in urine, and lack of association with outcome.
    Allory Y; Beukers W; Sagrera A; Flández M; Marqués M; Márquez M; van der Keur KA; Dyrskjot L; Lurkin I; Vermeij M; Carrato A; Lloreta J; Lorente JA; Carrillo-de Santa Pau E; Masius RG; Kogevinas M; Steyerberg EW; van Tilborg AA; Abas C; Orntoft TF; Zuiverloon TC; Malats N; Zwarthoff EC; Real FX
    Eur Urol; 2014 Feb; 65(2):360-6. PubMed ID: 24018021
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Upregulating mutations in the TERT promoter commonly occur in adult malignant gliomas and are strongly associated with total 1p19q loss.
    Arita H; Narita Y; Fukushima S; Tateishi K; Matsushita Y; Yoshida A; Miyakita Y; Ohno M; Collins VP; Kawahara N; Shibui S; Ichimura K
    Acta Neuropathol; 2013 Aug; 126(2):267-76. PubMed ID: 23764841
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Stratifin in ocular surface squamous neoplasia and its association with p53.
    Chauhan S; Sen S; Chauhan SS; Pushker N; Tandon R; Kashyap S; Vanathi M; Bajaj MS
    Acta Ophthalmol; 2021 Dec; 99(8):e1483-e1491. PubMed ID: 33769712
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.